Prise en charge du cancer de prostate métastasé androgéno-indépendant

25 novembre 2008

Auteurs : T. Lebret, A. Méjean
Référence : Prog Urol, 2008, 18, S343, suppl. S7
   
 
 

 

 
Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser

   

 

 
 
 

Références

 

Debes J.D., Tindall D.J. Mechanisms of androgen-refractory prostate cancer N Engl J Med 2004 ;  351 (15) : 1488-1490 [cross-ref]
 
Kyprianou N., English H.F., Isaacs J.T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation Cancer Res 1990 ;  50 (12) : 3748-3753
 
Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy Nat Med 2004 ;  10 (1) : 33-39Epub 2003 Dec 21. Comment in: Nat Med 2004;10(1):26-7.  [cross-ref]
 
Holzbeierlein J., Lal P., LaTulippe E., Smith A., Satagopan J., Zhang L., Ryan C., Smith S., Scher H., Scardino P., Reuter V., Gerald W.L. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance Am J Pathol 2004 ;  164 (1) : 217-227 [cross-ref]
 
Craft N., Shostak Y., Carey M., Sawyers C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase Nat Med 1999 ;  5 (3) : 280-285 [cross-ref]
 
Paule B. Reappraisal of the concept of hormone therapy in metastatic prostate cancer and implications for treatment Eur Urol 2005 ;  47 (6) : 729-735 [cross-ref]
 
Wen Y., Hu M.C.Makino K., Spohn B., Bartholomeusz G., Yan D.H., Hung M.C. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway Cancer Res 2000 ;  60 (24) : 6841-6845
 
Abreu-Martin M.T., Chari A., Palladino A.A., Craft N.A., Sawyers C.L. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer Mol Cell Biol 1999 ;  19 (7) : 5143-5154 [cross-ref]
 
Fang Y., Fliss A.E., Robins D.M., Caplan A.J. Hsp90 regulates androgen receptor hormone binding affinity in vivo J Biol Chem 1996 ;  271 (45) : 28697-28702 [cross-ref]
 
Lebret T., Watson R.W., Fitzpatrick J.M. Heat shock proteins: their role in urological tumors J Urol 2003 ;  169 (1) : 338-346 [cross-ref]
 
Hobisch A., Hoffmann J., Lambrinidis L., Eder I.E., Bartsch G., Klocker H., Culig Z. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model Urol Int 2000 ;  65 (2) : 73-79 [cross-ref]
 
Ma M.H., Yang H.H., Parker K., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents Clin Cancer Res 2003 ;  9 (3) : 1136-1144
 
Mitsiades N., Mitsiades C.S., Richardson P.G., McMullan C., Poulaki V., Fanourakis G., Schlossman R., Chauhan D., Munshi N.C., Hideshima T., Richon V.M., Marks P.A., Anderson K.C. Molecular sequelae of histone deacetylase inhibition in human malignant B cells Blood 2003 ;  101 (10) : 4055-4062 [cross-ref]
 
Mitchell S.H., Zhu W., Young C.Y. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells Cancer Res 1999 ;  59 (23) : 5892-5895
 
Zhu W., Zhang J.S., Young C.Y. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP Carcinogenesis 2001 ;  22 (9) : 1399-1403 [cross-ref]
 
Rimler A., Culig Z., Levy-Rimler G., Lupowitz Z., Klocker H., Matzkin H., Bartsch G., Zisapel N. Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity Prostate 2001 ;  49 (2) : 145-154 [cross-ref]
 
Haldar S., Chintapalli J., Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells Cancer Res 1996 ;  56 (6) : 1253-1255
 
Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis J Clin Oncol 2005 ;  23 : 8253-8261 [cross-ref]
 
Hadaschik B.A., Gleave M.E. Therapeutic options for hormonerefractory prostate cancer in 2007 Urol Oncol 2007 ;  25 (5) : 413-419 [cross-ref]
 
McConnell J, Denis L., Akaza H, Khoury S, Schalken P. Prostate cancer; 6th international consultation on new developpements in prostatic cancer and prostatic disease. 2006, 4:67-84
 
Dawson N.A. Response criteria in prostatic carcinoma Semin Oncol 1999 ;  26 (2) : 174-184
 
Oefelein M.G., Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm J Urol 2000 ;  164 (3Pt1) : 726-729 [cross-ref]
 
Ward J.F., Moul J.W. Treating the biochemical recurrence of prostate cancer after definitive primary therapy Clin Prostate Cancer 2005 ;  4 (1) : 38-44 [cross-ref]
 
Sharifi N., Gulley J.L., Dahut W.L. Androgen deprivation therapy for prostate cancer JAMA 2005 ;  294 (2) : 238-244 [cross-ref]
 
Alexandre I., Rixe O. Le cancer de prostate hormono-refractaire Ann Urol (Paris) 2007 ;  41 (2) : 47-55 [inter-ref]
 
Moul J.W., Fowler J.E. Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003 Urology 2003 ;  62 (6Suppl1) : 20-28 [inter-ref]
 
Kucuk O., Fisher E., Moinpour C.M., Coleman D., Hussain M.H., Sartor A.O., Chatta G.S., Lowe B.A., Eisenberger M.A., Crawford ED. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235) Urology 2001 ;  58 (1) : 53-58 [inter-ref]
 
Scher H.I., Liebertz C., Kelly W.K., Mazumdar M., Brett C., Schwartz L., Kolvenbag G., Shapiro L., Schwartz M. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease J Clin Oncol 1997 ;  15 (8) : 2928-2938 [cross-ref]
 
Miyake H., Hara I., Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer BJU Int 2005 ;  96 (6) : 791-795 [cross-ref]
 
Nakabayashi M., Regan M.M., Lifsey D., Kantoff P.W., Taplin M.E., Sartor O., Oh W.K. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer BJU Int 2005 ;  96 (6) : 783-786 [cross-ref]
 
Desai A., Stadler W.M., Vogelzang N.J. Nilutamide: possible utility as a second-line hormonal agent Urology 2001 ;  58 (6) : 1016-1020 [inter-ref]
 
Kassouf W., Tanguay S., Aprikian A.G. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails J Urol 2003 ;  169 : 1742-1744 [cross-ref]
 
Small E.J., Halabi S., Dawson N.A., Stadler W.M., Rini B.I., Picus J., Gable P., Torti F.M., Kaplan E., Vogelzang N.J. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583) J Clin Oncol 2004 ;  22 (6) : 1025-1033 [cross-ref]
 
Kelly W.K., Scher H.I. Prostate specific antigen decline after antiandrogen withdrawal J Urol 1993 ;  149 : 607-609 [cross-ref]
 
Small E.J., Baron A.D., Fippin L., Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal J Urol 1997 ;  157 (4) : 1204-1207 [cross-ref]
 
Small E.J., Halabi S., Dawson N.A., Stadler W.M., Rini B.I., Picus J., Gable P., Torti F.M., Kaplan E., Vogelzang N.J. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583) J Clin Oncol 2004 ;  22 (6) : 1025-1033 [cross-ref]
 
Millikan R., Baez L., Banerjee T., Wade J., Edwards K., Winn R., Smith T.L., Logothetis C. Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer Urol Oncol 2001 ;  6 (3) : 111-115 [cross-ref]
 
Harris K.A., Weinberg V., Bok R.A., Kakefuda M., Small E.J. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer J Urol 2002 ;  168 (2) : 542-545 [cross-ref]
 
Scholz M., Jennrich R., Strum S., Brosman S., Johnson H., Lam R. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone J Urol 2005 ;  173 (6) : 1947-1952 [cross-ref]
 
Venkitaraman R., Thomas K., Huddart R.A., et al. Efficacy of lowdose dexamethasone in castration-refractory prostate cancer BJU Int 2008 ;  101 : 440-443
 
Nishimura K., Nonomura N., Yasunaga Y., et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma Cancer 2000 ;  89 : 2570-2576 [cross-ref]
 
Yano A., Fuji Y., Iwai A., et al. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells Clin Cancer Res 2006 ;  12 : 3003-3009 [cross-ref]
 
Nishimura K., Nonomura N., Satoh E., et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer J Natl Cancer Inst 2001 ;  93 : 1739-1746 [cross-ref]
 
Venkitaraman R., Thomas K., Huddart R.A., Horwich A., Dearnaley D.P., Parker C.C. Efficacy of low-dose dexamethasone in castration-refractory prostate cancer BJU Int 2008 ;  101 (4) : 440-443
 
Smith D.C., Redman B.G., Flaherty L.E., et al. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer Urology 1998 ;  52 : 257-260 [inter-ref]
 
Oh W.K. The evolving role of estrogen therapy in prostate cancer Clin Prostate Cancer 2002 ;  1 (2) : 81-89 [cross-ref]
 
Hedlund P.O., Ala-Opas M., Brekkan E., et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer-Scandinavian Prostatic Cancer Group (SPCG) StudyNo 5 Scand J Urol Nephrol 2002 ;  36 (6) : 405-413 [cross-ref]
 
Ockrim J.L., Lalani E.N., Laniado M.E., Carter S.S., Abel P.D. Transdermal estradiol therapy for advanced prostate cancer--forward to the past? J Urol 2003 ;  169 (5) : 1735-1737 [cross-ref]
 
Ockrim J.L., Lalani el-N., Kakkar A.K., Abel P.D. Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism J Urol 2005 ;  174 (2) : 527-533 [cross-ref]
 
Berry W.R. Re-induction of hormonal sensitivity in hormonerefractory prostate cancer-fact or fiction? Nat Clin Pract Oncol 2005 ;  2 (4) : 180-181 [cross-ref]
 
   
 
 
   

 

© 2008  Elsevier Masson SAS. Tous droits réservés.